Here are relevant reports on : gastrointestinal-cancer-therapeutics-market
-
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Forecast to 2024
The Cancer Registry Software Market is projected to reach USD 91 million by 2024, at a CAGR of 10.4%. Factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However, factors such as privacy and data security-related concerns are expected to restrain the growth of this market to a certain extent.Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US).
- Published: March 2019
- Price: $ 11000
- TOC Available:
-
Surgical Anastomosis Devices Market by Product, (Surgical Sutures, Surgical Staplers), Application (Cardiovascular, Gastrointestinal) - Global Forecast to 2023
Anastomosis is a connection made surgically between adjacent blood vessels, parts of the intestine, or other channels of the body. It is achieved by surgically suturing or stapling the two ends of the channel to restore or form a new connection. Vascular anastomosis is performed to connect the blood vessels, for e.g. in cardio vascular surgeries such as by-pass surgery. Similarly, gastrointestinal anastomosis is performed for bowel re-sectioning, for e.g. in Gastrojejunostomy. With increasing ailments of cardiovascular diseases, gastrointestinal surgeries, and organ transplants has resulted in demand for anastomosis devices.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035
The global Next-generation drug conjugates (NDCs) market is projected to reach USD 42.55 billion by 2035, growing at a CAGR of 11.7% during the forecast period (2026–2035). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Clinical Microbiology Market by Product (Instrument (Incubators), Analyzer (Microscope), Reagent, Kits, Media], Disease Area (Respiratory, Gastrointestinal, STD, UTI), End User (Hospitals, Diagnostic Center, Research Institutes) - Global Forecast to 2030
The global clinical microbiology market, valued at US$5.08 billion in 2024, stood at US$5.33 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$7.34 billion by the end of the period. A key factor contributing to market growth is the rising technological advancements that have enabled the development of advanced microbial identification methods and improved antibiotic susceptibility testing.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Endoluminal Suturing Devices Market Size, Growth by Application (Bariatric, Gastrointestinal, Gastroesophageal Reflux Disease), End User (Hospitals, Clinics, Ambulatory Surgical Centers), Technology Analysis, Regulatory Landscape, Trends - Global Forecasts to 2027
The global endoluminal suturing devices market in terms of revenue was estimated to be worth $78 million in 2022 and is poised to reach $139 million by 2027, growing at a CAGR of 12.0% from 2022 to 2027. The prominent players in this market are Apollo Endosurgery, Inc. (US), Johnson & Johnson (US), Medtronic Plc (Ireland), Cook Group Incorporated (US), USGI Medical (US), Ovesco Endoscopy AG (Germany), Endo Tools Therapeutics S.A. (Belgium), ErgoSuture (US), and Sutrue Ltd. (UK).
- Published: August 2022
- Price: $ 4950
- TOC Available:
-
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2032
The global cancer biomarkers market is projected to reach USD 54.48 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2026–2032). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: May 2026
- Price: $ 7150
- TOC Available:
-
Minimally Invasive Surgical Instruments Market by Product (Handheld, Inflation Devices, Surgical Scopes), Type of Surgery (Cardiothoracic, Gastrointestinal, Bariatric, Orthopedic, Urological), Technology (Non-robotic, Robotic) - Global Forecast to 2029
The global minimally invasive surgical instruments market, valued at US$29.9 billion in 2023, stood at US$31.7 billion in 2024 and is projected to advance at a resilient CAGR of 9.5% from 2024 to 2029, culminating in a forecasted valuation of US$49.9 billion by the end of the period. The growth of this market is primarily fueled by the rising prevalence of surgical procedures globally, the advantages of minimally invasive surgery over traditional open techniques, and the increasing use of advanced robotics in ambulatory surgical centers.
- Published: June 2024
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
